Cid Inhibitors
Cyclic nucleotide phosphodiesterases (PDEs) play a crucial role in the regulation of intracellular signaling pathways by controlling the levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Among the various classes of PDE inhibitors, the class known as Cid Inhibitors refers to compounds specifically designed to target and modulate the activity of PDEs. These inhibitors act by interfering with the catalytic function of PDE enzymes, thereby influencing the degradation of cAMP and cGMP. By regulating these cyclic nucleotides, Cid Inhibitors have to modulate a wide range of cellular processes and signaling pathways.
Structurally, Cid Inhibitors can exhibit diverse chemical compositions, but they typically share a common mechanism of action. They function by binding to the active site of PDE enzymes, blocking the hydrolysis of cAMP and cGMP to their inactive forms. This leads to an accumulation of cyclic nucleotides in the cell, which, in turn, can impact downstream signaling cascades. Consequently, Cid Inhibitors are of significant interest in research and drug development due to regulate various physiological processes, including smooth muscle relaxation, platelet aggregation, and immune cell function. Understanding the precise mechanisms and specificities of Cid Inhibitors for different PDE isoforms is essential for harnessing their in various biological contexts, although their applications and implications are areas of ongoing investigation and study.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits BCR-ABL kinase, used for chronic myeloid leukemia by blocking the phosphorylation of downstream signaling proteins. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Targets multiple kinases, including RAF and VEGFR, to inhibit angiogenesis and tumor cell proliferation, studied in the research of advanced renal cell carcinoma and hepatocellular carcinoma. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Blocks EGFR tyrosine kinase activity, used in non-small cell lung cancer to hinder downstream signaling pathways and inhibit cancer cell growth. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Selectively inhibits mutated EGFR (T790M), delaying tumor growth in non-small cell lung cancer patients who have developed resistance to other EGFR inhibitors. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Inhibits multiple kinases, including BCR-ABL and SRC, used in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia by suppressing tyrosine kinase activity and downstream signaling. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
Selectively inhibits BCL-2, promoting apoptosis in B-cell lymphomas and chronic lymphocytic leukemia by blocking the anti-apoptotic effects of BCL-2 proteins. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Targets mTOR, a key regulator of cell growth and proliferation, used for various cancers and block organ rejection in transplant recipients by inhibiting mTOR-mediated signaling pathways. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Irreversibly inhibits Bruton's tyrosine kinase (BTK), suppressing B-cell signaling in B-cell malignancies such as chronic lymphocytic leukemia and mantle cell lymphoma. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Inhibits cyclin-dependent kinases (CDK4/6), leading to cell cycle arrest in estrogen receptor-positive breast cancer by blocking progression from G1 to S phase. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Selectively inhibits MEK1/2, a part of the MAPK pathway, used in melanoma and non-small cell lung cancer to disrupt downstream signaling and inhibit cell proliferation and survival. | ||||||